Search

Your search keyword '"Farago, Anna F"' showing total 319 results
Start Over Author "Farago, Anna F"
319 results on '"Farago, Anna F"'

1. A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

Author

Mansfield, Aaron S, Hong, David S, Hann, Christine L, Farago, Anna F, Beltran, Himisha, Waqar, Saiama N, Hendifar, Andrew E, Anthony, Lowell B, Taylor, Matthew H, Bryce, Alan H, Tagawa, Scott T, Lewis, Karl, Niu, Jiaxin, Chung, Christine H, Cleary, James M, Rossi, Michael, Ludwig, Carrianne, Valenzuela, Ricardo, Luo, Yan, and Aggarwal, Rahul

Subjects
Brain Disorders, Orphan Drug, Brain Cancer, Clinical Research, Rare Diseases, Clinical Trials and Supportive Activities, Cancer
Abstract

Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing tumors were enrolled in this phase I/II study (NCT02709889). The primary endpoint was safety. Two hundred patients were enrolled: 101 with NEC/NET (large-cell NEC, gastroenteropancreatic NEC, neuroendocrine prostate cancer, and other NEC/NET) and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and other). The recommended phase II dose (RP2D) was 0.3 mg/kg every 6 weeks (q6w) for two cycles. At the RP2D, grade 3/4 adverse events included anemia (17%), thrombocytopenia (15%), and elevated aspartate aminotransferase (8%). Responses were confirmed in 15/145 patients (10%) treated at 0.3 mg/kg, including 9/69 patients (13%) with NEC/NET. Rova-T at 0.3 mg/kg q6w had manageable toxicity, with antitumor activity observed in patients with NEC/NET, melanoma, MTC, and glioblastoma.

Published
2021

2. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

Author

Hong, David S, DuBois, Steven G, Kummar, Shivaani, Farago, Anna F, Albert, Catherine M, Rohrberg, Kristoffer S, van Tilburg, Cornelis M, Nagasubramanian, Ramamoorthy, Berlin, Jordan D, Federman, Noah, Mascarenhas, Leo, Geoerger, Birgit, Dowlati, Afshin, Pappo, Alberto S, Bielack, Stefan, Doz, François, McDermott, Ray, Patel, Jyoti D, Schilder, Russell J, Tahara, Makoto, Pfister, Stefan M, Witt, Olaf, Ladanyi, Marc, Rudzinski, Erin R, Nanda, Shivani, Childs, Barrett H, Laetsch, Theodore W, Hyman, David M, and Drilon, Alexander

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundThe selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.MethodsPatients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).FindingsBetween May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [

Published
2020

3. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Author

Doebele, Robert C, Drilon, Alexander, Paz-Ares, Luis, Siena, Salvatore, Shaw, Alice T, Farago, Anna F, Blakely, Collin M, Seto, Takashi, Cho, Byung Chul, Tosi, Diego, Besse, Benjamin, Chawla, Sant P, Bazhenova, Lyudmila, Krauss, John C, Chae, Young Kwang, Barve, Minal, Garrido-Laguna, Ignacio, Liu, Stephen V, Conkling, Paul, John, Thomas, Fakih, Marwan, Sigal, Darren, Loong, Herbert H, Buchschacher, Gary L, Garrido, Pilar, Nieva, Jorge, Steuer, Conor, Overbeck, Tobias R, Bowles, Daniel W, Fox, Elizabeth, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Demetri, George D, and investigators, trial

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Neurosciences, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aged, Antineoplastic Agents, Benzamides, Biomarkers, Tumor, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Female, Gene Fusion, Humans, Indazoles, Male, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasms, Protein Kinase Inhibitors, Receptor, trkA, Receptor, trkB, Receptor, trkC, Receptors, Nerve Growth Factor, Time Factors, Treatment Outcome, trial investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundEntrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including CNS activity due to its ability to penetrate the blood-brain barrier. We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated in three ongoing, early-phase trials.MethodsAn integrated database comprised the pivotal datasets of three, ongoing phase 1 or 2 clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2), which enrolled patients aged 18 years or older with metastatic or locally advanced NTRK fusion-positive solid tumours who received entrectinib orally at a dose of at least 600 mg once per day in a capsule. All patients had an Eastern Cooperative Oncology Group performance status of 0-2 and could have received previous anti-cancer therapy (except previous TRK inhibitors). The primary endpoints, the proportion of patients with an objective response and median duration of response, were evaluated by blinded independent central review in the efficacy-evaluable population (ie, patients with NTRK fusion-positive solid tumours who were TRK inhibitor-naive and had received at least one dose of entrectinib). Overall safety evaluable population included patients from STARTRK-1, STARTRK-2, ALKA-372-001, and STARTRK-NG (NCT02650401; treating young adult and paediatric patients [aged ≤21 years]), who received at least one dose of entrectinib, regardless of tumour type or gene rearrangement. NTRK fusion-positive safety evaluable population comprised all patients who have received at least one dose of entrectinib regardless of dose or follow-up. These ongoing studies are registered with ClinicalTrials.gov, NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012-000148-88 (ALKA-372-001).FindingsPatients were enrolled in ALKA-372-001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing). At the data cutoff date for this analysis (May 31, 2018) the efficacy-evaluable population comprised 54 adults with advanced or metastatic NTRK fusion-positive solid tumours comprising ten different tumour types and 19 different histologies. Median follow-up was 12.9 months (IQR 8·77-18·76). 31 (57%; 95% CI 43·2-70·8) of 54 patients had an objective response, of which four (7%) were complete responses and 27 (50%) partial reponses. Median duration of response was 10 months (95% CI 7·1 to not estimable). The most common grade 3 or 4 treatment-related adverse events in both safety populations were increased weight (seven [10%] of 68 patients in the NTRK fusion-positive safety population and in 18 [5%] of 355 patients in the overall safety-evaluable population) and anaemia (8 [12%] and 16 [5%]). The most common serious treatment-related adverse events were nervous system disorders (three [4%] of 68 patients and ten [3%] of 355 patients). No treatment-related deaths occurred.InterpretationEntrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile. These results show that entrectinib is a safe and active treatment option for patients with NTRK fusion-positive solid tumours. These data highlight the need to routinely test for NTRK fusions to broaden the therapeutic options available for patients with NTRK fusion-positive solid tumours.FundingIgnyta/F Hoffmann-La Roche.

Published
2020

4. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Author

Aix, Santiago Ponce, Ciuleanu, Tudor Eliade, Navarro, Alejandro, Cousin, Sophie, Bonanno, Laura, Smit, Egbert F, Chiappori, Alberto, Olmedo, Maria Eugenia, Horvath, Ildiko, Grohé, Christian, Farago, Anna F, López-Vilariño, José Antonio, Cullell-Young, Martin, Nieto, Antonio, Vasco, Noelia, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Carcereny, Enric, Roubec, Jaromir, Syrigos, Konstantinos, Lo, Gregory, Barneto, Isidoro, Pope, Anthony, Sánchez, Amparo, Kattan, Joseph, Zarogoulidis, Konstantinos, Waller, Cornelius F, Bischoff, Helge, Juan-Vidal, Oscar, Reinmuth, Niels, Dómine, Manuel, and Paz-Ares, Luis

Published
2023
Full Text
View/download PDF

5. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Author

Drilon, Alexander, Laetsch, Theodore W, Kummar, Shivaani, DuBois, Steven G, Lassen, Ulrik N, Demetri, George D, Nathenson, Michael, Doebele, Robert C, Farago, Anna F, Pappo, Alberto S, Turpin, Brian, Dowlati, Afshin, Brose, Marcia S, Mascarenhas, Leo, Federman, Noah, Berlin, Jordan, El-Deiry, Wafik S, Baik, Christina, Deeken, John, Boni, Valentina, Nagasubramanian, Ramamoorthy, Taylor, Matthew, Rudzinski, Erin R, Meric-Bernstam, Funda, Sohal, Davendra PS, Ma, Patrick C, Raez, Luis E, Hechtman, Jaclyn F, Benayed, Ryma, Ladanyi, Marc, Tuch, Brian B, Ebata, Kevin, Cruickshank, Scott, Ku, Nora C, Cox, Michael C, Hawkins, Douglas S, Hong, David S, and Hyman, David M

Subjects
Pediatric, Patient Safety, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Aged, Antineoplastic Agents, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Infant, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasms, Oncogene Proteins, Fusion, Protein Kinases, Pyrazoles, Pyrimidines, Receptor Protein-Tyrosine Kinases, Young Adult, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundFusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.MethodsWe enrolled patients with consecutively and prospectively identified TRK fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults. The primary end point for the combined analysis was the overall response rate according to independent review. Secondary end points included duration of response, progression-free survival, and safety.ResultsA total of 55 patients, ranging in age from 4 months to 76 years, were enrolled and treated. Patients had 17 unique TRK fusion-positive tumor types. The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment. At 1 year, 71% of the responses were ongoing and 55% of the patients remained progression-free. The median duration of response and progression-free survival had not been reached. At a median follow-up of 9.4 months, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative. Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients. No patient discontinued larotrectinib owing to drug-related adverse events.ConclusionsLarotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913 , NCT02637687 , and NCT02576431 .).

Published
2018

6. Supplementary Figure S9 from Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs

Author

Pal Choudhuri, Shreoshi, primary, Girard, Luc, primary, Lim, Jun Yi Stanley, primary, Wise, Jillian F., primary, Freitas, Braeden, primary, Yang, Di, primary, Wong, Edmond, primary, Hamilton, Seth, primary, Chien, Victor D., primary, Kim, Yoon Jung, primary, Gilbreath, Collin, primary, Zhong, Jun, primary, Phat, Sarah, primary, Myers, David T., primary, Christensen, Camilla L., primary, Mazloom-Farsibaf, Hanieh, primary, Stanzione, Marcello, primary, Wong, Kwok-Kin, primary, Hung, Yin P., primary, Farago, Anna F., primary, Meador, Catherine B., primary, Dyson, Nicholas J., primary, Lawrence, Michael S., primary, Wu, Sihan, primary, and Drapkin, Benjamin J., primary

Published
2024
Full Text
View/download PDF

7. Supplementary Tables from Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs

Author

Pal Choudhuri, Shreoshi, primary, Girard, Luc, primary, Lim, Jun Yi Stanley, primary, Wise, Jillian F., primary, Freitas, Braeden, primary, Yang, Di, primary, Wong, Edmond, primary, Hamilton, Seth, primary, Chien, Victor D., primary, Kim, Yoon Jung, primary, Gilbreath, Collin, primary, Zhong, Jun, primary, Phat, Sarah, primary, Myers, David T., primary, Christensen, Camilla L., primary, Mazloom-Farsibaf, Hanieh, primary, Stanzione, Marcello, primary, Wong, Kwok-Kin, primary, Hung, Yin P., primary, Farago, Anna F., primary, Meador, Catherine B., primary, Dyson, Nicholas J., primary, Lawrence, Michael S., primary, Wu, Sihan, primary, and Drapkin, Benjamin J., primary

Published
2024
Full Text
View/download PDF

8. New Approaches to SCLC Therapy: From the Laboratory to the Clinic

Author

Poirier, John T., George, Julie, Owonikoko, Taofeek K., Berns, Anton, Brambilla, Elisabeth, Byers, Lauren A., Carbone, David, Chen, Huanhuan J., Christensen, Camilla L., Dive, Caroline, Farago, Anna F., Govindan, Ramaswamy, Hann, Christine, Hellmann, Matthew D., Horn, Leora, Johnson, Jane E., Ju, Young S., Kang, Sumin, Krasnow, Mark, Lee, James, Lee, Se-Hoon, Lehman, Jonathan, Lok, Benjamin, Lovly, Christine, MacPherson, David, McFadden, David, Minna, John, Oser, Matthew, Park, Keunchil, Park, Kwon-Sik, Pommier, Yves, Quaranta, Vito, Ready, Neal, Sage, Julien, Scagliotti, Giorgio, Sos, Martin L., Sutherland, Kate D., Travis, William D., Vakoc, Christopher R., Wait, Sarah J., Wistuba, Ignacio, Wong, Kwok Kin, Zhang, Hua, Daigneault, Jillian, Wiens, Jacinta, Rudin, Charles M., and Oliver, Trudy G.

Published
2020
Full Text
View/download PDF

9. Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer

Author

Ricciuti, Biagio, Naqash, Abdul Rafeh, Naidoo, Jarushka, Sehgal, Kartik, Miller, Adam, Kehl, Kenneth, Venkatraman, Deepti, Sands, Jacob, Lamberti, Giuseppe, Recondo, Gonzalo, Zhang, Jiajia, Macherla, Shravanti, Baig, Sameer, Walker, Paul, Rangachari, Deepa, Gainor, Justin F., Costa, Daniel B., Rizvi, Naiyer, Sholl, Lynette M., Nishino, Mizuki, Henick, Brian, Farago, Anna F., and Awad, Mark M.

Published
2020
Full Text
View/download PDF

10. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs

Author

Pal Choudhuri, Shreoshi, primary, Girard, Luc, additional, Lim, Jun Yi Stanley, additional, Wise, Jillian F., additional, Freitas, Braeden, additional, Yang, Di, additional, Wong, Edmond, additional, Hamilton, Seth, additional, Chien, Victor D., additional, Kim, Yoon Jung, additional, Gilbreath, Collin, additional, Zhong, Jun, additional, Phat, Sarah, additional, Myers, David T., additional, Christensen, Camilla L., additional, Mazloom-Farsibaf, Hanieh, additional, Stanzione, Marcello, additional, Wong, Kwok-Kin, additional, Hung, Yin P., additional, Farago, Anna F., additional, Meador, Catherine B., additional, Dyson, Nicholas J., additional, Lawrence, Michael S., additional, Wu, Sihan, additional, and Drapkin, Benjamin J., additional

Published
2024
Full Text
View/download PDF

12. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses

Author

Joshi, Nikhil S, Akama-Garren, Elliot H, Lu, Yisi, Lee, Da-Yae, Chang, Gregory P, Li, Amy, DuPage, Michel, Tammela, Tuomas, Kerper, Natanya R, Farago, Anna F, Robbins, Rebecca, Crowley, Denise M, Bronson, Roderick T, and Jacks, Tyler

Subjects
Lung, Rare Diseases, Immunization, Lung Cancer, Cancer, 5.1 Pharmaceuticals, Aetiology, 2.1 Biological and endogenous factors, Development of treatments and therapeutic interventions, Inflammatory and immune system, Adenocarcinoma, Animals, Cell Proliferation, Cells, Cultured, Dendritic Cells, Flow Cytometry, Forkhead Transcription Factors, Immunohistochemistry, Luminescent Proteins, Lung Neoplasms, Lymphocyte Activation, Lymphocyte Depletion, Lymphocytes, Tumor-Infiltrating, Mice, Transgenic, Microscopy, Confocal, Neoplasms, T-Lymphocytes, T-Lymphocytes, Regulatory, Immunology
Abstract

Infiltration of regulatory T (Treg) cells into many tumor types correlates with poor patient prognoses. However, mechanisms of intratumoral Treg cell function remain to be elucidated. We investigated Treg cell function in a genetically engineered mouse model of lung adenocarcinoma and found that Treg cells suppressed anti-tumor responses in tumor-associated tertiary lymphoid structures (TA-TLSs). TA-TLSs have been described in human lung cancers, but their function remains to be determined. TLSs in this model were spatially associated with >90% of tumors and facilitated interactions between T cells and tumor-antigen-presenting dendritic cells (DCs). Costimulatory ligand expression by DCs and T cell proliferation rates increased in TA-TLSs upon Treg cell depletion, leading to tumor destruction. Thus, we propose that Treg cells in TA-TLSs can inhibit endogenous immune responses against tumors, and targeting these cells might provide therapeutic benefit for cancer patients.

Published
2015

15. Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification ofMYCparalogs

Author

Choudhuri, Shreoshi Pal, primary, Girard, Luc, additional, Lim, Jun Yi Stanley, additional, Wise, Jillian F., additional, Freitas, Braeden, additional, Yang, Di, additional, Wong, Edmond, additional, Hamilton, Seth, additional, Chien, Victor D., additional, Gilbreath, Collin, additional, Zhong, Jun, additional, Phat, Sarah, additional, Myers, David T., additional, Christensen, Camilla L., additional, Stanzione, Marcello, additional, Wong, Kwok-Kin, additional, Farago, Anna F., additional, Meador, Catherine B., additional, Dyson, Nicholas J., additional, Lawrence, Michael S., additional, Wu, Sihan, additional, and Drapkin, Benjamin J., additional

Published
2023
Full Text
View/download PDF

16. KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Author

Cassier, Philippe Alexandre, primary, Dooms, Christophe Alfons, additional, Gazzah, Anas, additional, Felip, Enriqueta, additional, Steeghs, Neeltje, additional, Rohrberg, Kristoffer Staal, additional, De Braud, Filippo G., additional, Solomon, Benjamin J., additional, Schuler, Martin H., additional, Tan, Daniel Shao-Weng, additional, Yamamoto, Noboru, additional, Loong, Herbert H. F., additional, Cho, Byoung Chul, additional, Wolf, Juergen, additional, Lin, Chia-Chi, additional, Negrao, Marcelo Vailati, additional, Werner, Lillian, additional, Cui, Xiaoming, additional, Farago, Anna F., additional, and de Miguel, Maria J., additional

Published
2023
Full Text
View/download PDF

17. Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Author

Weiss, Andreas, primary, Lorthiois, Edwige, primary, Barys, Louise, primary, Beyer, Kim S., primary, Bomio-Confaglia, Claudio, primary, Burks, Heather, primary, Chen, Xueying, primary, Cui, Xiaoming, primary, de Kanter, Ruben, primary, Dharmarajan, Lekshmi, primary, Fedele, Carmine, primary, Gerspacher, Marc, primary, Guthy, Daniel Alexander, primary, Head, Victoria, primary, Jaeger, Ashley, primary, Núñez, Eloísa Jiménez, primary, Kearns, Jeffrey D., primary, Leblanc, Catherine, primary, Maira, Sauveur-Michel, primary, Murphy, Jason, primary, Oakman, Helen, primary, Ostermann, Nils, primary, Ottl, Johannes, primary, Rigollier, Pascal, primary, Roman, Danielle, primary, Schnell, Christian, primary, Sedrani, Richard, primary, Shimizu, Toshio, primary, Stringer, Rowan, primary, Vaupel, Andrea, primary, Voshol, Hans, primary, Wessels, Peter, primary, Widmer, Toni, primary, Wilcken, Rainer, primary, Xu, Kun, primary, Zecri, Frederic, primary, Farago, Anna F., primary, Cotesta, Simona, primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Author

Weiss, Andreas, primary, Lorthiois, Edwige, primary, Barys, Louise, primary, Beyer, Kim S., primary, Bomio-Confaglia, Claudio, primary, Burks, Heather, primary, Chen, Xueying, primary, Cui, Xiaoming, primary, de Kanter, Ruben, primary, Dharmarajan, Lekshmi, primary, Fedele, Carmine, primary, Gerspacher, Marc, primary, Guthy, Daniel Alexander, primary, Head, Victoria, primary, Jaeger, Ashley, primary, Núñez, Eloísa Jiménez, primary, Kearns, Jeffrey D., primary, Leblanc, Catherine, primary, Maira, Sauveur-Michel, primary, Murphy, Jason, primary, Oakman, Helen, primary, Ostermann, Nils, primary, Ottl, Johannes, primary, Rigollier, Pascal, primary, Roman, Danielle, primary, Schnell, Christian, primary, Sedrani, Richard, primary, Shimizu, Toshio, primary, Stringer, Rowan, primary, Vaupel, Andrea, primary, Voshol, Hans, primary, Wessels, Peter, primary, Widmer, Toni, primary, Wilcken, Rainer, primary, Xu, Kun, primary, Zecri, Frederic, primary, Farago, Anna F., primary, Cotesta, Simona, primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

19. Data from Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

Author

Farago, Anna F., primary, Yeap, Beow Y., primary, Stanzione, Marcello, primary, Hung, Yin P., primary, Heist, Rebecca S., primary, Marcoux, J. Paul, primary, Zhong, Jun, primary, Rangachari, Deepa, primary, Barbie, David A., primary, Phat, Sarah, primary, Myers, David T., primary, Morris, Robert, primary, Kem, Marina, primary, Dubash, Taronish D., primary, Kennedy, Elizabeth A., primary, Digumarthy, Subba R., primary, Sequist, Lecia V., primary, Hata, Aaron N., primary, Maheswaran, Shyamala, primary, Haber, Daniel A., primary, Lawrence, Michael S., primary, Shaw, Alice T., primary, Mino-Kenudson, Mari, primary, Dyson, Nicholas J., primary, and Drapkin, Benjamin J., primary

Published
2023
Full Text
View/download PDF

20. Supplementary text from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts

Author

Drapkin, Benjamin J., primary, George, Julie, primary, Christensen, Camilla L., primary, Mino-Kenudson, Mari, primary, Dries, Ruben, primary, Sundaresan, Tilak, primary, Phat, Sarah, primary, Myers, David T., primary, Zhong, Jun, primary, Igo, Peter, primary, Hazar-Rethinam, Mehlika H., primary, Licausi, Joseph A., primary, Gomez-Caraballo, Maria, primary, Kem, Marina, primary, Jani, Kandarp N., primary, Azimi, Roxana, primary, Abedpour, Nima, primary, Menon, Roopika, primary, Lakis, Sotirios, primary, Heist, Rebecca S., primary, Büttner, Reinhard, primary, Haas, Stefan, primary, Sequist, Lecia V., primary, Shaw, Alice T., primary, Wong, Kwok-Kin, primary, Hata, Aaron N., primary, Toner, Mehmet, primary, Maheswaran, Shyamala, primary, Haber, Daniel A., primary, Peifer, Martin, primary, Dyson, Nicholas, primary, Thomas, Roman K., primary, and Farago, Anna F., primary

Published
2023
Full Text
View/download PDF

21. Data from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

22. Data from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts

Author

Drapkin, Benjamin J., primary, George, Julie, primary, Christensen, Camilla L., primary, Mino-Kenudson, Mari, primary, Dries, Ruben, primary, Sundaresan, Tilak, primary, Phat, Sarah, primary, Myers, David T., primary, Zhong, Jun, primary, Igo, Peter, primary, Hazar-Rethinam, Mehlika H., primary, Licausi, Joseph A., primary, Gomez-Caraballo, Maria, primary, Kem, Marina, primary, Jani, Kandarp N., primary, Azimi, Roxana, primary, Abedpour, Nima, primary, Menon, Roopika, primary, Lakis, Sotirios, primary, Heist, Rebecca S., primary, Büttner, Reinhard, primary, Haas, Stefan, primary, Sequist, Lecia V., primary, Shaw, Alice T., primary, Wong, Kwok-Kin, primary, Hata, Aaron N., primary, Toner, Mehmet, primary, Maheswaran, Shyamala, primary, Haber, Daniel A., primary, Peifer, Martin, primary, Dyson, Nicholas, primary, Thomas, Roman K., primary, and Farago, Anna F., primary

Published
2023
Full Text
View/download PDF

23. Data from Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non–Small Cell Lung Cancer

Author

Nangia, Varuna, primary, Siddiqui, Faria M., primary, Caenepeel, Sean, primary, Timonina, Daria, primary, Bilton, Samantha J., primary, Phan, Nicole, primary, Gomez-Caraballo, Maria, primary, Archibald, Hannah L., primary, Li, Chendi, primary, Fraser, Cameron, primary, Rigas, Diamanda, primary, Vajda, Kristof, primary, Ferris, Lorin A., primary, Lanuti, Michael, primary, Wright, Cameron D., primary, Raskin, Kevin A., primary, Cahill, Daniel P., primary, Shin, John H., primary, Keyes, Colleen, primary, Sequist, Lecia V., primary, Piotrowska, Zofia, primary, Farago, Anna F., primary, Azzoli, Christopher G., primary, Gainor, Justin F., primary, Sarosiek, Kristopher A., primary, Brown, Sean P., primary, Coxon, Angela, primary, Benes, Cyril H., primary, Hughes, Paul E., primary, and Hata, Aaron N., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Tables S3-S8 from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts

Author

Drapkin, Benjamin J., primary, George, Julie, primary, Christensen, Camilla L., primary, Mino-Kenudson, Mari, primary, Dries, Ruben, primary, Sundaresan, Tilak, primary, Phat, Sarah, primary, Myers, David T., primary, Zhong, Jun, primary, Igo, Peter, primary, Hazar-Rethinam, Mehlika H., primary, Licausi, Joseph A., primary, Gomez-Caraballo, Maria, primary, Kem, Marina, primary, Jani, Kandarp N., primary, Azimi, Roxana, primary, Abedpour, Nima, primary, Menon, Roopika, primary, Lakis, Sotirios, primary, Heist, Rebecca S., primary, Büttner, Reinhard, primary, Haas, Stefan, primary, Sequist, Lecia V., primary, Shaw, Alice T., primary, Wong, Kwok-Kin, primary, Hata, Aaron N., primary, Toner, Mehmet, primary, Maheswaran, Shyamala, primary, Haber, Daniel A., primary, Peifer, Martin, primary, Dyson, Nicholas, primary, Thomas, Roman K., primary, and Farago, Anna F., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non–Small Cell Lung Cancer

Author

Nangia, Varuna, primary, Siddiqui, Faria M., primary, Caenepeel, Sean, primary, Timonina, Daria, primary, Bilton, Samantha J., primary, Phan, Nicole, primary, Gomez-Caraballo, Maria, primary, Archibald, Hannah L., primary, Li, Chendi, primary, Fraser, Cameron, primary, Rigas, Diamanda, primary, Vajda, Kristof, primary, Ferris, Lorin A., primary, Lanuti, Michael, primary, Wright, Cameron D., primary, Raskin, Kevin A., primary, Cahill, Daniel P., primary, Shin, John H., primary, Keyes, Colleen, primary, Sequist, Lecia V., primary, Piotrowska, Zofia, primary, Farago, Anna F., primary, Azzoli, Christopher G., primary, Gainor, Justin F., primary, Sarosiek, Kristopher A., primary, Brown, Sean P., primary, Coxon, Angela, primary, Benes, Cyril H., primary, Hughes, Paul E., primary, and Hata, Aaron N., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures 1-11 from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts

Author

Drapkin, Benjamin J., primary, George, Julie, primary, Christensen, Camilla L., primary, Mino-Kenudson, Mari, primary, Dries, Ruben, primary, Sundaresan, Tilak, primary, Phat, Sarah, primary, Myers, David T., primary, Zhong, Jun, primary, Igo, Peter, primary, Hazar-Rethinam, Mehlika H., primary, Licausi, Joseph A., primary, Gomez-Caraballo, Maria, primary, Kem, Marina, primary, Jani, Kandarp N., primary, Azimi, Roxana, primary, Abedpour, Nima, primary, Menon, Roopika, primary, Lakis, Sotirios, primary, Heist, Rebecca S., primary, Büttner, Reinhard, primary, Haas, Stefan, primary, Sequist, Lecia V., primary, Shaw, Alice T., primary, Wong, Kwok-Kin, primary, Hata, Aaron N., primary, Toner, Mehmet, primary, Maheswaran, Shyamala, primary, Haber, Daniel A., primary, Peifer, Martin, primary, Dyson, Nicholas, primary, Thomas, Roman K., primary, and Farago, Anna F., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Tables 4-5 from Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

Author

Farago, Anna F., primary, Yeap, Beow Y., primary, Stanzione, Marcello, primary, Hung, Yin P., primary, Heist, Rebecca S., primary, Marcoux, J. Paul, primary, Zhong, Jun, primary, Rangachari, Deepa, primary, Barbie, David A., primary, Phat, Sarah, primary, Myers, David T., primary, Morris, Robert, primary, Kem, Marina, primary, Dubash, Taronish D., primary, Kennedy, Elizabeth A., primary, Digumarthy, Subba R., primary, Sequist, Lecia V., primary, Hata, Aaron N., primary, Maheswaran, Shyamala, primary, Haber, Daniel A., primary, Lawrence, Michael S., primary, Shaw, Alice T., primary, Mino-Kenudson, Mari, primary, Dyson, Nicholas J., primary, and Drapkin, Benjamin J., primary

Published
2023
Full Text
View/download PDF

28. Clinical Trial Protocol from Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

Author

Farago, Anna F., primary, Yeap, Beow Y., primary, Stanzione, Marcello, primary, Hung, Yin P., primary, Heist, Rebecca S., primary, Marcoux, J. Paul, primary, Zhong, Jun, primary, Rangachari, Deepa, primary, Barbie, David A., primary, Phat, Sarah, primary, Myers, David T., primary, Morris, Robert, primary, Kem, Marina, primary, Dubash, Taronish D., primary, Kennedy, Elizabeth A., primary, Digumarthy, Subba R., primary, Sequist, Lecia V., primary, Hata, Aaron N., primary, Maheswaran, Shyamala, primary, Haber, Daniel A., primary, Lawrence, Michael S., primary, Shaw, Alice T., primary, Mino-Kenudson, Mari, primary, Dyson, Nicholas J., primary, and Drapkin, Benjamin J., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure Legends from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figures 1 - 2 from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data from Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

Author

Farago, Anna F., primary, Yeap, Beow Y., primary, Stanzione, Marcello, primary, Hung, Yin P., primary, Heist, Rebecca S., primary, Marcoux, J. Paul, primary, Zhong, Jun, primary, Rangachari, Deepa, primary, Barbie, David A., primary, Phat, Sarah, primary, Myers, David T., primary, Morris, Robert, primary, Kem, Marina, primary, Dubash, Taronish D., primary, Kennedy, Elizabeth A., primary, Digumarthy, Subba R., primary, Sequist, Lecia V., primary, Hata, Aaron N., primary, Maheswaran, Shyamala, primary, Haber, Daniel A., primary, Lawrence, Michael S., primary, Shaw, Alice T., primary, Mino-Kenudson, Mari, primary, Dyson, Nicholas J., primary, and Drapkin, Benjamin J., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Tables 1-6 from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Author

Drilon, Alexander, primary, Siena, Salvatore, primary, Ou, Sai-Hong Ignatius, primary, Patel, Manish, primary, Ahn, Myung Ju, primary, Lee, Jeeyun, primary, Bauer, Todd M., primary, Farago, Anna F., primary, Wheler, Jennifer J., primary, Liu, Stephen V., primary, Doebele, Robert, primary, Giannetta, Laura, primary, Cerea, Giulio, primary, Marrapese, Giovanna, primary, Schirru, Michele, primary, Amatu, Alessio, primary, Bencardino, Katia, primary, Palmeri, Laura, primary, Sartore-Bianchi, Andrea, primary, Vanzulli, Angelo, primary, Cresta, Sara, primary, Damian, Silvia, primary, Duca, Matteo, primary, Ardini, Elena, primary, Li, Gang, primary, Christiansen, Jason, primary, Kowalski, Karey, primary, Johnson, Ann D., primary, Patel, Rupal, primary, Luo, David, primary, Chow-Maneval, Edna, primary, Hornby, Zachary, primary, Multani, Pratik S., primary, Shaw, Alice T., primary, and De Braud, Filippo G., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Tables from Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Author

Dagogo-Jack, Ibiayi, primary, Rooney, Marguerite, primary, Lin, Jessica J., primary, Nagy, Rebecca J., primary, Yeap, Beow Y., primary, Hubbeling, Harper, primary, Chin, Emily, primary, Ackil, Jennifer, primary, Farago, Anna F., primary, Hata, Aaron N., primary, Lennerz, Jochen K., primary, Gainor, Justin F., primary, Lanman, Richard B., primary, and Shaw, Alice T., primary

Published
2023
Full Text
View/download PDF

34. Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

Author

Singh, Harshabad, primary, Li, Yvonne Y., primary, Spurr, Liam F., primary, Shinagare, Atul B., primary, Abhyankar, Ritika, primary, Reilly, Emma, primary, Brais, Lauren K., primary, Nag, Anwesha, primary, Ducar, Matthew D., primary, Thorner, Aaron R., primary, Shapiro, Geoffrey I., primary, Keller, Rachel B., primary, Siletti, Cheta, primary, Clark, Jeffrey W., primary, Farago, Anna F., primary, Lin, Jessica J., primary, Demetri, George D., primary, Gujrathi, Rahul, primary, Kulke, Matthew H., primary, MacConaill, Laura E., primary, Ligon, Azra H., primary, Sicinska, Ewa, primary, Meyerson, Matthew L., primary, Meyerhardt, Jeffrey A., primary, Cherniack, Andrew D., primary, Wolpin, Brian M., primary, Ng, Kimmie, primary, Giannakis, Marios, primary, Hornick, Jason L., primary, and Cleary, James M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figures from Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Author

Dagogo-Jack, Ibiayi, primary, Rooney, Marguerite, primary, Lin, Jessica J., primary, Nagy, Rebecca J., primary, Yeap, Beow Y., primary, Hubbeling, Harper, primary, Chin, Emily, primary, Ackil, Jennifer, primary, Farago, Anna F., primary, Hata, Aaron N., primary, Lennerz, Jochen K., primary, Gainor, Justin F., primary, Lanman, Richard B., primary, and Shaw, Alice T., primary

Published
2023
Full Text
View/download PDF

36. Table S1 from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Author

Gainor, Justin F., primary, Shaw, Alice T., primary, Sequist, Lecia V., primary, Fu, Xiujun, primary, Azzoli, Christopher G., primary, Piotrowska, Zofia, primary, Huynh, Tiffany G., primary, Zhao, Ling, primary, Fulton, Linnea, primary, Schultz, Katherine R., primary, Howe, Emily, primary, Farago, Anna F., primary, Sullivan, Ryan J., primary, Stone, James R., primary, Digumarthy, Subba, primary, Moran, Teresa, primary, Hata, Aaron N., primary, Yagi, Yukako, primary, Yeap, Beow Y., primary, Engelman, Jeffrey A., primary, and Mino-Kenudson, Mari, primary

Published
2023
Full Text
View/download PDF

37. Figure S3 from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Author

Gainor, Justin F., primary, Shaw, Alice T., primary, Sequist, Lecia V., primary, Fu, Xiujun, primary, Azzoli, Christopher G., primary, Piotrowska, Zofia, primary, Huynh, Tiffany G., primary, Zhao, Ling, primary, Fulton, Linnea, primary, Schultz, Katherine R., primary, Howe, Emily, primary, Farago, Anna F., primary, Sullivan, Ryan J., primary, Stone, James R., primary, Digumarthy, Subba, primary, Moran, Teresa, primary, Hata, Aaron N., primary, Yagi, Yukako, primary, Yeap, Beow Y., primary, Engelman, Jeffrey A., primary, and Mino-Kenudson, Mari, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data-clean from Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Author

Morgensztern, Daniel, primary, Besse, Benjamin, primary, Greillier, Laurent, primary, Santana-Davila, Rafael, primary, Ready, Neal, primary, Hann, Christine L., primary, Glisson, Bonnie S., primary, Farago, Anna F., primary, Dowlati, Afshin, primary, Rudin, Charles M., primary, Le Moulec, Sylvestre, primary, Lally, Satwant, primary, Yalamanchili, Sreeni, primary, Wolf, Jürgen, primary, Govindan, Ramaswamy, primary, and Carbone, David P., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure Legends from Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Author

Dagogo-Jack, Ibiayi, primary, Rooney, Marguerite, primary, Lin, Jessica J., primary, Nagy, Rebecca J., primary, Yeap, Beow Y., primary, Hubbeling, Harper, primary, Chin, Emily, primary, Ackil, Jennifer, primary, Farago, Anna F., primary, Hata, Aaron N., primary, Lennerz, Jochen K., primary, Gainor, Justin F., primary, Lanman, Richard B., primary, and Shaw, Alice T., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

Author

Singh, Harshabad, primary, Li, Yvonne Y., primary, Spurr, Liam F., primary, Shinagare, Atul B., primary, Abhyankar, Ritika, primary, Reilly, Emma, primary, Brais, Lauren K., primary, Nag, Anwesha, primary, Ducar, Matthew D., primary, Thorner, Aaron R., primary, Shapiro, Geoffrey I., primary, Keller, Rachel B., primary, Siletti, Cheta, primary, Clark, Jeffrey W., primary, Farago, Anna F., primary, Lin, Jessica J., primary, Demetri, George D., primary, Gujrathi, Rahul, primary, Kulke, Matthew H., primary, MacConaill, Laura E., primary, Ligon, Azra H., primary, Sicinska, Ewa, primary, Meyerson, Matthew L., primary, Meyerhardt, Jeffrey A., primary, Cherniack, Andrew D., primary, Wolpin, Brian M., primary, Ng, Kimmie, primary, Giannakis, Marios, primary, Hornick, Jason L., primary, and Cleary, James M., primary

Published
2023
Full Text
View/download PDF

41. Supplemental Figure Legends from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Author

Gainor, Justin F., primary, Shaw, Alice T., primary, Sequist, Lecia V., primary, Fu, Xiujun, primary, Azzoli, Christopher G., primary, Piotrowska, Zofia, primary, Huynh, Tiffany G., primary, Zhao, Ling, primary, Fulton, Linnea, primary, Schultz, Katherine R., primary, Howe, Emily, primary, Farago, Anna F., primary, Sullivan, Ryan J., primary, Stone, James R., primary, Digumarthy, Subba, primary, Moran, Teresa, primary, Hata, Aaron N., primary, Yagi, Yukako, primary, Yeap, Beow Y., primary, Engelman, Jeffrey A., primary, and Mino-Kenudson, Mari, primary

Published
2023
Full Text
View/download PDF

42. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

Author

Faber, Anthony C., Farago, Anna F., Costa, Carlotta, Dastur, Anahita, Gomez-Caraballo, Maria, Robbins, Rebecca, Wagner, Bethany L., Rideout, William M., Jakubik, Charles T., Ham, Jungoh, Edelman, Elena J., Ebi, Hiromichi, Yeo, Alan T., Hata, Aaron N., Song, Youngchul, Patel, Neha U., March, Ryan J., Tam, Ah Ting, Milano, Randy J., Boisvert, Jessica L., Hicks, Mark A., Elmiligy, Sarah, Malstrom, Scott E., Rivera, Miguel N., Harada, Hisashi, Windle, Brad E., Ramaswamy, Sridhar, Benes, Cyril H., Jacks, Tyler, and Engelman, Jeffrey A.

Published
2015

44. Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer

Author

Stanzione, Marcello, primary, Zhong, Jun, additional, Wong, Edmond, additional, LaSalle, Thomas J., additional, Wise, Jillian F., additional, Simoneau, Antoine, additional, Myers, David T., additional, Phat, Sarah, additional, Sade-Feldman, Moshe, additional, Lawrence, Michael S., additional, Hadden, M. Kyle, additional, Zou, Lee, additional, Farago, Anna F., additional, Dyson, Nicholas J., additional, and Drapkin, Benjamin J., additional

Published
2022
Full Text
View/download PDF

45. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Author

Weiss, Andreas, primary, Lorthiois, Edwige, additional, Barys, Louise, additional, Beyer, Kim S., additional, Bomio-Confaglia, Claudio, additional, Burks, Heather, additional, Chen, Xueying, additional, Cui, Xiaoming, additional, de Kanter, Ruben, additional, Dharmarajan, Lekshmi, additional, Fedele, Carmine, additional, Gerspacher, Marc, additional, Guthy, Daniel Alexander, additional, Head, Victoria, additional, Jaeger, Ashley, additional, Núñez, Eloísa Jiménez, additional, Kearns, Jeffrey D., additional, Leblanc, Catherine, additional, Maira, Sauveur-Michel, additional, Murphy, Jason, additional, Oakman, Helen, additional, Ostermann, Nils, additional, Ottl, Johannes, additional, Rigollier, Pascal, additional, Roman, Danielle, additional, Schnell, Christian, additional, Sedrani, Richard, additional, Shimizu, Toshio, additional, Stringer, Rowan, additional, Vaupel, Andrea, additional, Voshol, Hans, additional, Wessels, Peter, additional, Widmer, Toni, additional, Wilcken, Rainer, additional, Xu, Kun, additional, Zecri, Frederic, additional, Farago, Anna F., additional, Cotesta, Simona, additional, and Brachmann, Saskia M., additional

Published
2022
Full Text
View/download PDF

46. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor

Author

Alvarez-Breckenridge, Christopher, Miller, Julie J., Nayyar, Naema, Gill, Corey M., Kaneb, Andrew, D’Andrea, Megan, Le, Long P., Lee, Jesse, Cheng, Ju, Zheng, Zongli, Butler, William E., Multani, Pratik, Chow Maneval, Edna, Ha Paek, Sun, Toyota, Brian D., Dias-Santagata, Dora, Santagata, Sandro, Romero, Javier, Shaw, Alice T., Farago, Anna F., Yip, Stephen, Cahill, Daniel P., Batchelor, Tracy T., Iafrate, A. John, and Brastianos, Priscilla K.

Published
2017
Full Text
View/download PDF

47. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Author

Bunn, Paul A., Jr., Minna, John D., Augustyn, Alexander, Gazdar, Adi F., Ouadah, Youcef, Krasnow, Mark A., Berns, Anton, Brambilla, Elisabeth, Rekhtman, Natasha, Massion, Pierre P., Niederst, Matthew, Peifer, Martin, Yokota, Jun, Govindan, Ramaswamy, Poirier, John T., Byers, Lauren A., Wynes, Murry W., McFadden, David G., MacPherson, David, Hann, Christine L., Farago, Anna F., Dive, Caroline, Teicher, Beverly A., Peacock, Craig D., Johnson, Jane E., Cobb, Melanie H., Wendel, Hans-Guido, Spigel, David, Sage, Julien, Yang, Ping, Pietanza, Catherine M., Krug, Lee M., Heymach, John, Ujhazy, Peter, Zhou, Caicun, Goto, Koichi, Dowlati, Afshin, Christensen, Camilla Laulund, Park, Keunchil, Einhorn, Lawrence H., Edelman, Martin J., Giaccone, Giuseppe, Gerber, David E., Salgia, Ravi, Owonikoko, Taofeek, Malik, Shakun, Karachaliou, Niki, Gandara, David R., Slotman, Ben J., Blackhall, Fiona, Goss, Glenwood, Thomas, Roman, Rudin, Charles M., and Hirsch, Fred R.

Published
2016
Full Text
View/download PDF

48. Abstract LBA038: KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation

Author

Solomon, Benjamin, primary, Heist, Rebecca S, additional, Tan, Daniel SW, additional, Cassier, Philippe A, additional, Dooms, Christophe, additional, Van Cutsem, Eric, additional, Steuer, Conor E, additional, Steeghs, Neeltje, additional, Schuler, Martin, additional, Gazzah, Anas, additional, Wermke, Martin, additional, Felip, Enriqueta, additional, Loong, Herbert HF, additional, De Miguel Luken, Maria J, additional, Soo, Ross A, additional, Jaeger, Ashley, additional, Xu, Kun, additional, Chen, Xueying, additional, Cui, Xiaoming, additional, Burks, Heather, additional, Farago, Anna F, additional, and Shimizu, Toshio, additional

Published
2021
Full Text
View/download PDF

49. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Author

Dziadziuszko, Rafal, primary, Krebs, Matthew G., additional, De Braud, Filippo, additional, Siena, Salvatore, additional, Drilon, Alexander, additional, Doebele, Robert C., additional, Patel, Manish R., additional, Cho, Byoung Chul, additional, Liu, Stephen V., additional, Ahn, Myung-Ju, additional, Chiu, Chao-Hua, additional, Farago, Anna F., additional, Lin, Chia-Chi, additional, Karapetis, Christos S., additional, Li, Yu-Chung, additional, Day, Bann-mo, additional, Chen, David, additional, Wilson, Timothy R., additional, and Barlesi, Fabrice, additional

Published
2021
Full Text
View/download PDF

50. New approaches to small cell lung cancer therapy : from the laboratory to the clinic

Author

Poirier, John T., George, Julie, Owonikoko, Taofeek K., Berns, Anton, Brambilla, Elisabeth, Byers, Lauren Averett, Carbone, David, Chen, Huanhuan Joyce, Christensen, Camilla L., Dive, Caroline, Farago, Anna F., Govindan, Ramaswamy, Hann, Christine, Hellmann, Matthew D., Horn, Leora, Johnson, Jane E., Ju, Young Seok, Kang, Sumin, Krasnow, Mark, Lee, James, Lee, Se-Hoon, Lehman, Jonathan, Lok, Benjamin, Lovly, Christine, MacPherson, David, McFadden, David, Minna, John, Oser, Matthew, Park, Keunchil, Park, Kwon-Sik, Pommier, Yves, Quaranta, Vito, Ready, Neal, Sage, Julien, Scagliotti, Giorgio, Sos, Martin L., Sutherland, Kate D., Travis, William D., Vakoc, Christopher R., Wait, Sarah J., Wistuba, Ignacio, Wong, Kwok Kin, Zhang, Hua, Daigneault, Jillian, Wiens, Jacinta, Rudin, Charles M., and Oliver, Trudy G.

Subjects
Lung Neoplasms, Humans, Neoplasm Recurrence, Local, Precision Medicine, Laboratories, Small Cell Lung Carcinoma, Article
Abstract

Small cell lung cancer patient outcomes have not yet been significantly impacted by the revolution in precision oncology, primarily due to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the clinic. While these results are encouraging, many patients do not respond to or rapidly recur after current regimens, necessitating alternative or complementary therapeutic strategies. In this review, we discuss ongoing investigations into the pathobiology of this recalcitrant cancer and the therapeutic vulnerabilities that are exposed by the disease state. Included within this discussion is a snapshot of the current biomarker and clinical trial landscapes for small cell lung cancer. Finally, we identify key knowledge gaps that should be addressed in order to advance the field in pursuit of reduced small cell lung cancer mortality. This review largely summarizes work presented at the Third Biennial IASLC Small Cell Lung Cancer Meeting.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results